Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials
Research article
[키워드] activate
acute respiratory distress syndrome
Alpha
alveolar
Anti-inflammatory therapy
Anti-viral
anti-viral effect
anticoagulant therapy
anticoagulation
approach
ARDS
ARDSacute respiratory distress syndrome
Bacterial
Beta
Blood
C-reactive protein
Care
Cell
chemokines
clinical outcomes
clinically
Coagulopathy
Comorbidities
Computerized tomography
concerning
Coronaviruses
COVID-19
COVID-19 infection
CoVscoronaviruses
criteria
CRPC-reactive protein
CTcomputerized tomography
CXCL10chemokines
CXCL9
cytokine
D-dimer
diagnose
Diagnosis
diagnostic
DICdisseminated intravascular coagulation
Digital
Disseminated intravascular coagulation
distress
effective
elevated
emboli
extreme
General population
GGOground glass opacities
gluthathione
ground glass opacities
GSHgluthathione
Health
Health authority
healthy
help
high mortality rate
highest
hypothetical
ICUIntensive Care Unit
identify
IL-10interleukin 10
IL-12interleukin 12
IL-18interleukin 18
IL-1βinterleukin 1 beta
IL-33interleukin 33
IL-6interleukin 6
IL-7Interleukin 7
IL-8interleukin 8
immune
immune function
immunomodulatory
implementation
increase in
individual
individuals
Inflammation
intensive care unit
interleukin 1 beta
Interleukin 10
interleukin 12
interleukin 18
interleukin 33
interleukin 6
Interleukin 7
interleukin 8
Intervention
Isolation
Ivermectin
lactic dehydrogenase
LDHlactic dehydrogenase
LDLyme disease
literature review
Lyme disease
macrophage activation syndrome
MASmacrophage activation syndrome
MERS coronavirus
MERS-CovMERS coronavirus
morbidity and mortality
Multiorgan dysfunction
N-acetyl-cysteine
NACN-acetyl-cysteine
NCPnovel coronavirus pneumonia
New
NF-κB
novel coronavirus pneumonia
NSnutritional support
nutraceutical
nutritional support
organ
outcomes
oxygen
Oxygenation
pandemic
Pathways
Patient
performed
physical distancing
Pneumonia
precursor
Prevent
protocol
questionnaire
Randomized controlled trial
randomized trial
randomized, controlled trials
required
resource
respiratory therapy
resulting
risk
SARS-CoV-2severe acute respiratory syndrome coronavirus 2
scored
screening questionnaire
second
Sepsis
serum
severe acute respiratory syndrome coronavirus 2
severe complication
silent
statistical
statistically
Stress
sulforaphane
Support
Symptom
symptomatic infection
TGFβtransforming growth factor beta
the disease
therapy
thrombotic event
TNF-αtumor necrosis factor alpha
transforming growth factor beta
Transmission
Treatment
Treatment strategies
tumor necrosis factor alpha
ventilator
vital sign
Vitamin C
WHOWorld Health Organization
with COVID-19
World Health Organization
[DOI] 10.1016/j.mehy.2020.109851 [Article Type] Research article
[DOI] 10.1016/j.mehy.2020.109851 [Article Type] Research article